The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pravastatin Market Research Report 2024
Synopsis
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease.
The global Pravastatin market was valued at US$ 547 million in 2023 and is anticipated to reach US$ 835 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
North American market for Pravastatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pravastatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pravastatin include Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals and Glenmark, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pravastatin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pravastatin.
Report Scope
The Pravastatin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pravastatin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pravastatin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
TEVA
SANDOZ
APOTEX
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Cipla Inc.
Lupin Pharmaceuticals
Glenmark
Mylan
Aurobindo Pharma
Accord Healthcare
Upsher-Smith Laboratories
Hisun
Jiangxi Boyaseehot Pharmaceutical
Shanghai Shyndec Pharmaceutical
Daiichi Sankyo
North China Pharmaceutical Group
Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pravastatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pravastatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease.
The global Pravastatin market was valued at US$ 547 million in 2023 and is anticipated to reach US$ 835 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
North American market for Pravastatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pravastatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pravastatin include Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals and Glenmark, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pravastatin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pravastatin.
Report Scope
The Pravastatin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pravastatin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pravastatin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
TEVA
SANDOZ
APOTEX
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Cipla Inc.
Lupin Pharmaceuticals
Glenmark
Mylan
Aurobindo Pharma
Accord Healthcare
Upsher-Smith Laboratories
Hisun
Jiangxi Boyaseehot Pharmaceutical
Shanghai Shyndec Pharmaceutical
Daiichi Sankyo
North China Pharmaceutical Group
Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pravastatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pravastatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pravastatin Market Overview
1.1 Product Overview and Scope of Pravastatin
1.2 Pravastatin Segment by Type
1.2.1 Global Pravastatin Market Value Comparison by Type (2024-2030)
1.2.2 10mg Tablet
1.2.3 20mg Tablet
1.2.4 40mg Tablet
1.2.5 80mg Tablet
1.3 Pravastatin Segment by Application
1.3.1 Global Pravastatin Market Value by Application: (2024-2030)
1.3.2 Adults
1.3.3 Children
1.4 Global Pravastatin Market Size Estimates and Forecasts
1.4.1 Global Pravastatin Revenue 2019-2030
1.4.2 Global Pravastatin Sales 2019-2030
1.4.3 Global Pravastatin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pravastatin Market Competition by Manufacturers
2.1 Global Pravastatin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pravastatin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pravastatin Average Price by Manufacturers (2019-2024)
2.4 Global Pravastatin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pravastatin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pravastatin, Product Type & Application
2.7 Pravastatin Market Competitive Situation and Trends
2.7.1 Pravastatin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pravastatin Players Market Share by Revenue
2.7.3 Global Pravastatin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pravastatin Retrospective Market Scenario by Region
3.1 Global Pravastatin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pravastatin Global Pravastatin Sales by Region: 2019-2030
3.2.1 Global Pravastatin Sales by Region: 2019-2024
3.2.2 Global Pravastatin Sales by Region: 2025-2030
3.3 Global Pravastatin Global Pravastatin Revenue by Region: 2019-2030
3.3.1 Global Pravastatin Revenue by Region: 2019-2024
3.3.2 Global Pravastatin Revenue by Region: 2025-2030
3.4 North America Pravastatin Market Facts & Figures by Country
3.4.1 North America Pravastatin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pravastatin Sales by Country (2019-2030)
3.4.3 North America Pravastatin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pravastatin Market Facts & Figures by Country
3.5.1 Europe Pravastatin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pravastatin Sales by Country (2019-2030)
3.5.3 Europe Pravastatin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pravastatin Market Facts & Figures by Country
3.6.1 Asia Pacific Pravastatin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pravastatin Sales by Country (2019-2030)
3.6.3 Asia Pacific Pravastatin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pravastatin Market Facts & Figures by Country
3.7.1 Latin America Pravastatin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pravastatin Sales by Country (2019-2030)
3.7.3 Latin America Pravastatin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pravastatin Market Facts & Figures by Country
3.8.1 Middle East and Africa Pravastatin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pravastatin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pravastatin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pravastatin Sales by Type (2019-2030)
4.1.1 Global Pravastatin Sales by Type (2019-2024)
4.1.2 Global Pravastatin Sales by Type (2025-2030)
4.1.3 Global Pravastatin Sales Market Share by Type (2019-2030)
4.2 Global Pravastatin Revenue by Type (2019-2030)
4.2.1 Global Pravastatin Revenue by Type (2019-2024)
4.2.2 Global Pravastatin Revenue by Type (2025-2030)
4.2.3 Global Pravastatin Revenue Market Share by Type (2019-2030)
4.3 Global Pravastatin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pravastatin Sales by Application (2019-2030)
5.1.1 Global Pravastatin Sales by Application (2019-2024)
5.1.2 Global Pravastatin Sales by Application (2025-2030)
5.1.3 Global Pravastatin Sales Market Share by Application (2019-2030)
5.2 Global Pravastatin Revenue by Application (2019-2030)
5.2.1 Global Pravastatin Revenue by Application (2019-2024)
5.2.2 Global Pravastatin Revenue by Application (2025-2030)
5.2.3 Global Pravastatin Revenue Market Share by Application (2019-2030)
5.3 Global Pravastatin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol-Myers Squibb Pravastatin Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 TEVA
6.2.1 TEVA Corporation Information
6.2.2 TEVA Description and Business Overview
6.2.3 TEVA Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 TEVA Pravastatin Product Portfolio
6.2.5 TEVA Recent Developments/Updates
6.3 SANDOZ
6.3.1 SANDOZ Corporation Information
6.3.2 SANDOZ Description and Business Overview
6.3.3 SANDOZ Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 SANDOZ Pravastatin Product Portfolio
6.3.5 SANDOZ Recent Developments/Updates
6.4 APOTEX
6.4.1 APOTEX Corporation Information
6.4.2 APOTEX Description and Business Overview
6.4.3 APOTEX Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 APOTEX Pravastatin Product Portfolio
6.4.5 APOTEX Recent Developments/Updates
6.5 Dr. Reddy's Laboratories
6.5.1 Dr. Reddy's Laboratories Corporation Information
6.5.2 Dr. Reddy's Laboratories Description and Business Overview
6.5.3 Dr. Reddy's Laboratories Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Dr. Reddy's Laboratories Pravastatin Product Portfolio
6.5.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.6 Zydus Pharmaceuticals
6.6.1 Zydus Pharmaceuticals Corporation Information
6.6.2 Zydus Pharmaceuticals Description and Business Overview
6.6.3 Zydus Pharmaceuticals Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Zydus Pharmaceuticals Pravastatin Product Portfolio
6.6.5 Zydus Pharmaceuticals Recent Developments/Updates
6.7 Cipla Inc.
6.6.1 Cipla Inc. Corporation Information
6.6.2 Cipla Inc. Description and Business Overview
6.6.3 Cipla Inc. Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Inc. Pravastatin Product Portfolio
6.7.5 Cipla Inc. Recent Developments/Updates
6.8 Lupin Pharmaceuticals
6.8.1 Lupin Pharmaceuticals Corporation Information
6.8.2 Lupin Pharmaceuticals Description and Business Overview
6.8.3 Lupin Pharmaceuticals Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lupin Pharmaceuticals Pravastatin Product Portfolio
6.8.5 Lupin Pharmaceuticals Recent Developments/Updates
6.9 Glenmark
6.9.1 Glenmark Corporation Information
6.9.2 Glenmark Description and Business Overview
6.9.3 Glenmark Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Glenmark Pravastatin Product Portfolio
6.9.5 Glenmark Recent Developments/Updates
6.10 Mylan
6.10.1 Mylan Corporation Information
6.10.2 Mylan Description and Business Overview
6.10.3 Mylan Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Mylan Pravastatin Product Portfolio
6.10.5 Mylan Recent Developments/Updates
6.11 Aurobindo Pharma
6.11.1 Aurobindo Pharma Corporation Information
6.11.2 Aurobindo Pharma Pravastatin Description and Business Overview
6.11.3 Aurobindo Pharma Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Aurobindo Pharma Pravastatin Product Portfolio
6.11.5 Aurobindo Pharma Recent Developments/Updates
6.12 Accord Healthcare
6.12.1 Accord Healthcare Corporation Information
6.12.2 Accord Healthcare Pravastatin Description and Business Overview
6.12.3 Accord Healthcare Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Accord Healthcare Pravastatin Product Portfolio
6.12.5 Accord Healthcare Recent Developments/Updates
6.13 Upsher-Smith Laboratories
6.13.1 Upsher-Smith Laboratories Corporation Information
6.13.2 Upsher-Smith Laboratories Pravastatin Description and Business Overview
6.13.3 Upsher-Smith Laboratories Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Upsher-Smith Laboratories Pravastatin Product Portfolio
6.13.5 Upsher-Smith Laboratories Recent Developments/Updates
6.14 Hisun
6.14.1 Hisun Corporation Information
6.14.2 Hisun Pravastatin Description and Business Overview
6.14.3 Hisun Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hisun Pravastatin Product Portfolio
6.14.5 Hisun Recent Developments/Updates
6.15 Jiangxi Boyaseehot Pharmaceutical
6.15.1 Jiangxi Boyaseehot Pharmaceutical Corporation Information
6.15.2 Jiangxi Boyaseehot Pharmaceutical Pravastatin Description and Business Overview
6.15.3 Jiangxi Boyaseehot Pharmaceutical Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Jiangxi Boyaseehot Pharmaceutical Pravastatin Product Portfolio
6.15.5 Jiangxi Boyaseehot Pharmaceutical Recent Developments/Updates
6.16 Shanghai Shyndec Pharmaceutical
6.16.1 Shanghai Shyndec Pharmaceutical Corporation Information
6.16.2 Shanghai Shyndec Pharmaceutical Pravastatin Description and Business Overview
6.16.3 Shanghai Shyndec Pharmaceutical Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Shanghai Shyndec Pharmaceutical Pravastatin Product Portfolio
6.16.5 Shanghai Shyndec Pharmaceutical Recent Developments/Updates
6.17 Daiichi Sankyo
6.17.1 Daiichi Sankyo Corporation Information
6.17.2 Daiichi Sankyo Pravastatin Description and Business Overview
6.17.3 Daiichi Sankyo Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Daiichi Sankyo Pravastatin Product Portfolio
6.17.5 Daiichi Sankyo Recent Developments/Updates
6.18 North China Pharmaceutical Group
6.18.1 North China Pharmaceutical Group Corporation Information
6.18.2 North China Pharmaceutical Group Pravastatin Description and Business Overview
6.18.3 North China Pharmaceutical Group Pravastatin Sales, Revenue and Gross Margin (2019-2024)
6.18.4 North China Pharmaceutical Group Pravastatin Product Portfolio
6.18.5 North China Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pravastatin Industry Chain Analysis
7.2 Pravastatin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pravastatin Production Mode & Process
7.4 Pravastatin Sales and Marketing
7.4.1 Pravastatin Sales Channels
7.4.2 Pravastatin Distributors
7.5 Pravastatin Customers
8 Pravastatin Market Dynamics
8.1 Pravastatin Industry Trends
8.2 Pravastatin Market Drivers
8.3 Pravastatin Market Challenges
8.4 Pravastatin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
